Apollo Eyes $20B DePuy Synthes Acquisition

Apollo Global Management is reportedly in advanced discussions to acquire Johnson & Johnson's prominent orthopedics division, DePuy Synthes, in a deal potentially valued at approximately $20 billion. This significant private equity transaction underscores the ongoing strategic realignments within the healthcare sector and the persistent appetite for established, high-revenue medical device businesses.

The potential acquisition, if finalized, would represent one of the largest private equity-backed healthcare deals in recent memory. DePuy Synthes, a major player in the orthopedic market, generated substantial revenue, reportedly reaching $9.3 billion in sales during the 2025 fiscal year. This robust financial performance makes it an attractive target for firms like Apollo, known for its strategic investments in companies with strong cash flow generation and operational improvement potential.

Johnson & Johnson's consideration of divesting DePuy Synthes aligns with its broader strategy, announced in October 2025, to streamline its MedTech portfolio. The healthcare giant aims to sharpen its focus on higher-growth, higher-margin market segments. The separation of its orthopedics unit, initially projected to take 18 to 24 months, could materialize through various structures, including a spin-off into an independent public entity or a direct sale, such as the one being explored with Apollo.

This move by Apollo highlights a key trend: private capital firms are actively pursuing large-scale healthcare assets. The orthopedic sector, in particular, benefits from demographic tailwinds, including an aging global population and increasing demand for joint replacement and reconstructive surgeries. The market for orthopedic devices is substantial, with global revenues in the tens of billions of dollars annually, and is projected to continue its steady expansion.

Should the deal with Apollo proceed, it would significantly reshape the competitive dynamics within the orthopedics industry. Johnson & Johnson, meanwhile, intends to concentrate its resources on six core growth areas: Oncology, Immunology, Neuroscience, Cardiovascular, Surgery, and Vision. This strategic pivot allows the company to dedicate capital and innovation efforts to areas promising greater long-term returns and market leadership.

While negotiations are reportedly underway, the outcome remains uncertain. The possibility of other bidders emerging cannot be discounted as Johnson & Johnson evaluates its options. Nevertheless, the reported interest from Apollo Global Management signals a strong conviction in the enduring value and future prospects of DePuy Synthes within the global medical technology arena.